NasdaqCM:IMUXBiotechs
Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic’s (IMUX) Long-Term Value Proposition?
Immunic, Inc. recently secured a key European patent for its lead asset vidofludimus calcium, aligning protection with existing U.S. coverage and potentially extending exclusivity into the 2040s for chronic inflammatory and autoimmune indications.
This expanded intellectual property protection materially underpins the company’s core therapeutic franchise by lengthening its runway to develop and, if approved, commercialize its main clinical asset.
Against this backdrop, we’ll explore how the...